Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease

NCTID NCT05956626 (View at clinicaltrials.gov)
Description
Indication Stargardt Disease (Juvenile Macular Degeneration)
Compound Name OCU410ST
Sponsor Ocugen
Funder Type Industry
Status
Recruiting
Enrollment Count 42

Therapy Information

Target Gene/Variant RORA
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Subretinal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV5
Editor Type
Dose 1 3.75 x 10^10 vg/mL
Dose 2 7.5 x 10^10 vg/mL
Dose 3 2.25 x 10^11 vg/mL
Dose 4
Dose 5

Study Record Dates

Current Stage Phase1, Phase2
Submit Date 2023-06-30
Completion Date 2025-10-28
Last Update 2024-03-12

Participation Criteria

Eligible Age 6 Years - 65 Years
Standard Ages Child, Adult, Older adult
Eligible Sex ALL

Locations

No.of Trial Sites 6
Locations United States

Regulatory Information

Has US IND True
Recent Updates FDA granted ODD, moving to Phase 2 with the medium and high doses

Resources/Links

Patents
  • US20210123077A1
News and Press Releases
Preclinical Publications